Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Serina Therapeutics (SER) Debt to Equity (2017 - 2025)

Serina Therapeutics' Debt to Equity history spans 9 years, with the latest figure at $1.64 for Q3 2025.

  • For Q3 2025, Debt to Equity rose 303.41% year-over-year to $1.64; the TTM value through Sep 2025 reached $1.64, up 303.41%, while the annual FY2022 figure was -$0.48, 7.09% up from the prior year.
  • Debt to Equity for Q3 2025 was $1.64 at Serina Therapeutics, up from -$0.81 in the prior quarter.
  • Across five years, Debt to Equity topped out at $1.64 in Q3 2025 and bottomed at -$1.2 in Q1 2021.
  • The 5-year median for Debt to Equity is -$0.81 (2024), against an average of -$0.6.
  • The largest annual shift saw Debt to Equity tumbled 1112.26% in 2024 before it soared 303.41% in 2025.
  • A 5-year view of Debt to Equity shows it stood at -$0.52 in 2021, then increased by 7.09% to -$0.48 in 2022, then surged by 86.13% to -$0.07 in 2023, then tumbled by 1112.26% to -$0.81 in 2024, then soared by 303.41% to $1.64 in 2025.
  • Per Business Quant, the three most recent readings for SER's Debt to Equity are $1.64 (Q3 2025), -$0.81 (Q3 2024), and -$0.68 (Q2 2024).